News & Videos - LIPELLA PHARMACEUTICALS INC. - English

PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26 th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright’s conference is for qualified investors, and Lipella will be giving a virtual presentation and management will be available for one-on-one meetings onsite. For more information and/or to register...

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available PITTSBURGH, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic...

LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases 5 th International Consultation on Interstitial Cystitis Japan runs Aug. 21-23 in Kyoto PITTSBURGH, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for...

PITTSBURGH, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects...

PITTSBURGH, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.62...

PITTSBURGH, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.62 per share (or pre-funded warrant in lieu thereof) in a...

PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). This chronic inflammatory condition, which affects over 6 million Americans, is characterized by mouth mucous...

Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating...

PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, taking place from May 31 - June 4 in Chicago, IL, and online. Lipella’s abstract, titled “Intravesical Administration of Pembrolizumab for...

PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024. The...

PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School of Medicine; and Pradeep Tyagi, PhD, MBA, Professor...

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment...

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10, an intravesical liposomal formulation of...

PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GVHD). Lipella’s clinical study, titled, A...

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET. Dr. Chancellor’s presentation will be titled: “Urologist Talks Bladder Cancer and Lasting Side...

PITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations granted. A highlight of the year includes...